Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Capital Expenditures (2016 - 2026)

Lexaria Bioscience's Capital Expenditures history spans 10 years, with the latest figure at $40816.0 for Q1 2026.

  • Quarterly results put Capital Expenditures at $40816.0 for Q1 2026, up 4081500.0% from a year ago — trailing twelve months through Feb 2026 was $40816.0 (down 39.67% YoY), and the annual figure for FY2025 was $24646.0, down 42.7%.
  • Capital Expenditures for Q1 2026 was $40816.0 at Lexaria Bioscience, up from $1.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $43014.0 in Q3 2024 to a low of -$1.0 in Q2 2025.
  • The 5-year median for Capital Expenditures is $10030.5 (2022), against an average of $14904.1.
  • The sharpest move saw Capital Expenditures plummeted 100.0% in 2025, then skyrocketed 4081500.0% in 2026.
  • Year by year, Capital Expenditures stood at $20500.0 in 2022, then crashed by 35.38% to $13248.0 in 2023, then skyrocketed by 86.03% to $24645.0 in 2024, then plummeted by 100.0% to $1.0 in 2025, then skyrocketed by 4081500.0% to $40816.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $40816.0, $1.0, and -$1.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.